Tahseen Mozaffar, MD
Neuromuscular Medicine · Orange, CANPI 1356421515
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $270,843 of the $427,862 with a category attached, or 63.3%. 29 manufacturers reported payments, led by Sanofi at 30.1% of the total. Reporting peaked in 2023 at $95,706 and has fallen 52.2% since, to $45,792 in 2025. Among neuromuscular medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $1097.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$129K
- Amicus Therapeutics, Inc.$119K
- AstraZeneca$44K
- Argenx US, Inc.$27K
- Spark Therapeutics, Inc.$20K
- UCB, Inc.$16K
- plus $73K from 23 others
Across 369 payments — averaging $7666.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amicus Therapeutics, Inc.$874K
- Sanofi$818K
- Argenx US, Inc.$414K
- Ultragenyx Pharmaceutical Inc.$150K
- Spark Therapeutics, Inc.$83K
- Sanofi US Services Inc.$70K
- plus $419K from 13 others
What the payments were for
- Consulting fees$270,84363%
- Speaking & faculty fees$82,76019%
- Travel & lodging$62,88015%
- Food & beverage$11,2263%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 83 | $128,809 |
| Amicus Therapeutics, Inc. | 54 | $118,575 |
| AstraZeneca | 48 | $43,689 |
| Argenx US, Inc. | 54 | $27,334 |
| Spark Therapeutics, Inc. | 9 | $19,792 |
| UCB, Inc. | 18 | $16,482 |
| Grifols USA, LLC | 40 | $13,718 |
| Amgen(2 entities) | 4 | $7,416 |
| Merck | 10 | $7,342 |
| Regeneron | 8 | $7,099 |
| Sanofi-aventis U.S. LLC | 4 | $6,896 |
| Tanabe Pharma America, Inc. | 8 | $4,653 |
| Sanofi US Services Inc. | 2 | $4,558 |
| UCB SA | 1 | $4,230 |
| CSL Behring | 11 | $3,882 |
| Zogenix Inc. | 1 | $2,500 |
| Ipsen Innovation | 1 | $2,275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,519 |
| Sarepta Therapeutics, Inc. | 8 | $1,427 |
| Mirum Pharmaceuticals, Inc. | 1 | $1,400 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,260 |
| Janssen Scientific Affairs, LLC | 1 | $1,250 |
| Genentech, Inc. | 9 | $841 |
| Octapharma USA, Inc. | 4 | $305 |
| Johnson & Johnson | 3 | $257 |
| Catalyst Pharmaceuticals, Inc. | 2 | $164 |
| Biogen | 1 | $121 |
| Akcea Therapeutics, Inc. | 1 | $68 |
| Travere Therapeutics, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIZYME$55,562
- POMBILITI$55,348
- OPFOLDA$55,348
- SOLIRIS$31,853
- NEXVIAZYME$24,332
- VYVGART$19,245
- Gamunex-C$13,147
- ULTOMIRIS$6,253
- Radicava$4,507
- UPLIZNA$4,436
- VYVGART HYTRULO$3,674
- Hizentra$3,670
- DISEASE STATE$3,284
- Fintepla$2,500
- IQIRVO$2,275
- GALAFOLD$2,224
- Rystiggo$1,740
- EVRYSDI$692
- Exondys 51$340
- Enspryng$149
How this compares
$427,862 in reported general payments places this provider in the 95th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumizymeAlglucosidase Alfa | 25 | $1,409,716 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $500,223 |
| Radicava OrsEdaravone | 20 | $267,904 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $237,795 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 34 | $176,816 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $35,274 |
| ProvigilModafinil | 11 | $25,965 |
| Sirolimus | 13 | $13,342 |
| Pyridostigmine Bromide | 37 | $2,077 |
| Riluzole | 15 | $1,462 |
| Azathioprine | 13 | $1,303 |
| Mexiletine Hcl | 18 | $726 |
| MethotrexateMethotrexate Sodium | 16 | $681 |
| Prednisone | 17 | $362 |
| Gabapentin | 19 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiLumizyme | $128,809 | $1,409,71625 claims |
| CSL BehringPrivigen, Hizentra | $3,882 | $738,01845 claims |
| Grifols USA, LLCGamunex-C | $13,718 | $176,81634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Orange
- Ali HabibOrange$445K
- Namita GoyalOrange$174K
- Jay HanOrange$126K
- Khalid AlrasheedOrange$75K
- Jeffrey MullenOrange$13K
- Jonathan CauchiOrange$895
- Mona Rezaei MirghaedOrange$673
- Samir MacwanRancho Mirage$983K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.